vs
Side-by-side financial comparison of Blue Foundry Bancorp (BLFY) and Foghorn Therapeutics Inc. (FHTX). Click either name above to swap in a different company.
Blue Foundry Bancorp is the larger business by last-quarter revenue ($13.3M vs $9.2M, roughly 1.4× Foghorn Therapeutics Inc.). Blue Foundry Bancorp runs the higher net margin — -27.4% vs -234.3%, a 206.9% gap on every dollar of revenue. On growth, Foghorn Therapeutics Inc. posted the faster year-over-year revenue change (223.8% vs 34.2%). Over the past eight quarters, Foghorn Therapeutics Inc.'s revenue compounded faster (35.3% CAGR vs 16.0%).
Blue Foundry Bancorp is a regional bank holding company based in New Jersey, United States. It offers a comprehensive range of personal and commercial banking products, including deposit accounts, consumer loans, mortgage services, and business financing solutions, serving local individual consumers and small to medium-sized enterprises.
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.
BLFY vs FHTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.3M | $9.2M |
| Net Profit | $-3.5M | $-21.7M |
| Gross Margin | — | — |
| Operating Margin | — | -258.2% |
| Net Margin | -27.4% | -234.3% |
| Revenue YoY | 34.2% | 223.8% |
| Net Profit YoY | -30.6% | -11.1% |
| EPS (diluted) | $-0.18 | $-0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.3M | $9.2M | ||
| Q3 25 | $12.6M | $8.2M | ||
| Q2 25 | $12.0M | $7.6M | ||
| Q1 25 | $11.1M | $6.0M | ||
| Q4 24 | $9.9M | $2.9M | ||
| Q3 24 | $9.5M | $7.8M | ||
| Q2 24 | $10.1M | $6.9M | ||
| Q1 24 | $9.9M | $5.0M |
| Q4 25 | $-3.5M | $-21.7M | ||
| Q3 25 | $-1.9M | $-15.8M | ||
| Q2 25 | $-2.0M | $-17.9M | ||
| Q1 25 | $-2.7M | $-18.8M | ||
| Q4 24 | $-2.7M | $-19.5M | ||
| Q3 24 | $-4.0M | $-19.1M | ||
| Q2 24 | $-2.3M | $-23.0M | ||
| Q1 24 | $-2.8M | $-25.0M |
| Q4 25 | — | -258.2% | ||
| Q3 25 | — | -226.9% | ||
| Q2 25 | — | -279.2% | ||
| Q1 25 | — | -385.0% | ||
| Q4 24 | — | -840.5% | ||
| Q3 24 | — | -305.5% | ||
| Q2 24 | — | -386.6% | ||
| Q1 24 | — | -558.3% |
| Q4 25 | -27.4% | -234.3% | ||
| Q3 25 | -14.8% | -194.4% | ||
| Q2 25 | -16.2% | -237.3% | ||
| Q1 25 | -24.2% | -316.4% | ||
| Q4 24 | -28.4% | -682.9% | ||
| Q3 24 | -42.7% | -244.9% | ||
| Q2 24 | -23.2% | -333.6% | ||
| Q1 24 | -28.8% | -495.4% |
| Q4 25 | $-0.18 | $-0.35 | ||
| Q3 25 | $-0.10 | $-0.25 | ||
| Q2 25 | $-0.10 | $-0.28 | ||
| Q1 25 | $-0.13 | $-0.30 | ||
| Q4 24 | $-0.12 | $-0.23 | ||
| Q3 24 | $-0.19 | $-0.31 | ||
| Q2 24 | $-0.11 | $-0.45 | ||
| Q1 24 | $-0.13 | $-0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $53.1M | $80.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $312.7M | $-108.5M |
| Total Assets | $2.2B | $198.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.1M | $80.9M | ||
| Q3 25 | $44.1M | $89.3M | ||
| Q2 25 | $41.9M | $72.6M | ||
| Q1 25 | $46.2M | $61.0M | ||
| Q4 24 | $42.5M | $55.5M | ||
| Q3 24 | $76.1M | $57.7M | ||
| Q2 24 | $60.3M | $138.9M | ||
| Q1 24 | $53.8M | $79.3M |
| Q4 25 | $312.7M | $-108.5M | ||
| Q3 25 | $314.4M | $-89.7M | ||
| Q2 25 | $321.3M | $-76.7M | ||
| Q1 25 | $326.7M | $-61.7M | ||
| Q4 24 | $332.2M | $-45.5M | ||
| Q3 24 | $339.3M | $-28.3M | ||
| Q2 24 | $345.6M | $-14.3M | ||
| Q1 24 | $350.2M | $-97.5M |
| Q4 25 | $2.2B | $198.1M | ||
| Q3 25 | $2.2B | $205.0M | ||
| Q2 25 | $2.1B | $226.2M | ||
| Q1 25 | $2.1B | $258.7M | ||
| Q4 24 | $2.1B | $284.0M | ||
| Q3 24 | $2.1B | $308.4M | ||
| Q2 24 | $2.0B | $328.6M | ||
| Q1 24 | $2.0B | $255.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.0M | $-22.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-8.0M | $-22.3M | ||
| Q3 25 | $-255.0K | $-18.9M | ||
| Q2 25 | $2.0M | $-21.0M | ||
| Q1 25 | $-3.8M | $-24.0M | ||
| Q4 24 | $5.1M | $-24.5M | ||
| Q3 24 | $-3.7M | $-21.0M | ||
| Q2 24 | $14.1M | $-25.5M | ||
| Q1 24 | $-4.9M | $-29.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-21.0M | ||
| Q1 25 | — | $-24.0M | ||
| Q4 24 | $4.9M | $-25.0M | ||
| Q3 24 | — | $-21.3M | ||
| Q2 24 | — | $-25.6M | ||
| Q1 24 | $-4.9M | $-29.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -278.2% | ||
| Q1 25 | — | -403.2% | ||
| Q4 24 | 49.8% | -875.3% | ||
| Q3 24 | — | -273.0% | ||
| Q2 24 | — | -371.0% | ||
| Q1 24 | -49.3% | -583.1% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 0.5% | ||
| Q4 24 | 1.4% | 16.8% | ||
| Q3 24 | — | 4.0% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | 0.1% | 2.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
